We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-0.78%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$357M
AUM Growth
-$64.5M
Cap. Flow
-$58.5M
Cap. Flow %
-16.36%
Top 10 Hldgs %
65.85%
Holding
90
New
23
Increased
14
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$9.89M
2
IMMU
Immunomedics Inc
IMMU
+$7.7M
3
KITE
Kite Pharma, Inc.
KITE
+$6.12M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$3.75M
5
ARGX icon
argenx
ARGX
+$3.18M

Top Sells

Rank Stock Value
1
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$9.77M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.62M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$5.98M
4
MRVL icon
Marvell Technology
MRVL
+$5.34M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.58M

Sector Composition

Rank Sector Weight
1 Healthcare 60.37%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYGN icon
51
PUT
Myriad Genetics
MYGN
$285M
$501K 0.14%
+19,400
New +$412K
CYTK icon
52
PUT
Cytokinetics
CYTK
$10.4B
$484K 0.14%
+40,000
New +$556K
IMGN
53
CALL
DELISTED
Immunogen Inc
IMGN
$356K 0.1%
+50,000
New +$229K
NDRM
54
PUT
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$299K 0.08%
+10,000
New +$259K
SGMO
55
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$264K 0.07%
+30,000
New +$192K
EPIX
56
DELISTED
ESSA Pharma
EPIX
$242K 0.07%
22,100
-8,165
-27% -$267K
MNKD icon
57
PUT
MannKind Corp
MNKD
$1.17B
$46K 0.01%
+32,300
New +$41.6K
OTLK icon
58
Outlook Therapeutics
OTLK
$171M
$29K 0.01%
182
– –
ONSIW
59
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$17K ﹤0.01%
96,833
– –
ONSIZ
60
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$9K ﹤0.01%
96,833
– –
ACAD icon
61
CALL
Acadia Pharmaceuticals
ACAD
$4.39B
– –
-210,000
Closed -$7.22M
AEHR icon
62
Aehr Test Systems
AEHR
$2.99B
– –
-122,000
Closed -$587K
AUPH icon
63
Aurinia Pharmaceuticals
AUPH
$1.87B
– –
-400,000
Closed -$2.94M
BCRX icon
64
CALL
BioCryst Pharmaceuticals
BCRX
$2.24B
– –
-325,000
Closed -$2.73M
CLSD
65
DELISTED
Clearside Biomedical
CLSD
– –
-11,667
Closed -$1.39M
CRBP icon
66
PUT
Corbus Pharmaceuticals
CRBP
$165M
– –
-9,667
Closed -$2.39M
DBVT
67
CALL
DBV Technologies
DBVT
$804M
– –
-3,000
Closed -$1.06M
EVH icon
68
CALL
Evolent Health
EVH
$353M
– –
-80,000
Closed -$1.78M
MRVL icon
69
CALL
Marvell Technology
MRVL
$174B
– –
-147,500
Closed -$2.25M
MRVL icon
70
Marvell Technology
MRVL
$174B
– –
-350,000
Closed -$5.34M
NKTR icon
71
PUT
Nektar Therapeutics
NKTR
$2.38B
– –
-5,107
Closed -$1.8M
OMER icon
72
CALL
Omeros
OMER
$909M
– –
-30,000
Closed -$454K
RMTI icon
73
PUT
Rockwell Medical
RMTI
$28.5M
– –
-1,273
Closed -$876K
SAGE
74
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-20,000
Closed -$1.42M
XBIT icon
75
CALL
XBiotech
XBIT
$68M
– –
-60,000
Closed -$989K
1 2
3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Acuta Capital Partners held 90 positions worth $357M, down 15% from $422M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Acuta Capital Partners withdrew a net $58.5M in Q2 2017, closing 30 positions and reducing 14 holdings. Its most notable exit was Oxford Immunotec Global PLC Ordinary Shares, an estimated $5.98M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Technology.

Against the trend, Acuta Capital Partners opened a new position in Kite Pharma, Inc. worth $7.78M.

  • Acuta Capital Partners's largest Q2 2017 buy was Kite Pharma, Inc.: 75,000 shares worth $7.78M.
  • Acuta Capital Partners added most to Ascendis Pharma A/S in Q2 2017, an estimated $9.89M increase.
  • Acuta Capital Partners's biggest Q2 2017 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $9.77M.
  • Acuta Capital Partners fully exited Oxford Immunotec Global PLC Ordinary Shares in Q2 2017, selling an estimated $5.98M.
  • Acuta Capital Partners's ten largest holdings make up 66% of its $357M portfolio in Q2 2017.
  • Acuta Capital Partners opened 23 new positions and closed 30 in Q2 2017.
  • Acuta Capital Partners's portfolio value fell 15% quarter-over-quarter to $357M.

Based on Acuta Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.